Haydarpaşa Numune Education and Research Hospital
Istanbul, Turkey (Türkiye)
NCT Number: NCT06595771
-------------Obstructive sleep apnea syndrome (OSAS) is a syndrome characterized by recurrent complete (apnea) or partial (hypopnea) upper respiratory tract obstruction episodes during sleep and a decrease in blood oxygen saturation. It has been suggested that nocturnal arterial desaturation in patients with OSAS is effective on pain. Intermittent hypoxia and oxidative stress occur in patients with OSAS. Intermittent hypoxia occurring in patients with OSAS causes increased levels of HIF-1-α and mitochondrial reactive oxygen products, resulting in the formation, processing, and formation of central and peripheral synthesis. When the literature is examined, pressure-related pain threshold was measured with algometer in female patients diagnosed with sleep apnea and in the control group, and it was found lower in patients with OSAS.
Fibromyalgia Syndrome (FMS) is a clinical picture with many symptoms such as chronic widespread pain, fatigue, sleep disturbance, cognitive dysfunction. Similar sleep patterns were observed in FMS and OSAS.
In addition to sleep symptoms such as the presence of a similar sleep pattern, a feeling of rest and daytime sleepiness in cases of OSAS and FMS, it has been suggested that these two diseases may be related to each other. Studies examining the relationship between OSAS and FMS syndrome, including sleep disturbance and pain symptoms, are rare in the literature. In the current literature, there are various limitations such as insufficient number of cases, significant difference between demographic characteristics such as gender, ethnicity, age.
Therefore, primary goal of this study is to investigate the association of FMS in patients diagnosed with OSAS. The secondary aim is to investigate the effect of CPAP (Continuous Positive Airway Pressure) treatment on pain sensitivity and symptom severity, functional level, depression in patients diagnosed with FMS, and to investigate the relationship between these parameters and polysomnographic data
Looking for future studies?
Notify Me30 year–65 year
All sexes
Observational
Istanbul, Turkey (Türkiye)
Patients between 30-65 years of age who were diagnosed with OSAS according to American Academy of Sleep Medicine (AASM) criteria and who had clinical symptoms of OSAS for at least 1 year before diagnosis will be performed. All OSAS patients recommended and not recommended for CPAP treatment in the sleep clinic will be evaluated according to the American Rheumatology Association (ACR) 1990 and 2016 criteria for FMS. Patients meeting both criteria will be accepted as FMS.
Demographic data and polysomnographic data of patients such as age, height, weight, BMI, occupation, educational status (polysomnographic data (AHI, min. O₂ sat, O₂ saturation <90% elapsed time and percentage, sleep latency, sleep efficacy, REM, nREM1,2,3 polysomnographic data such as times, REM latency, severity of OSAS) will be recorded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
continuous positive airway pressure is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people who are able to breathe spontaneously on their own, but need help keeping their airway unobstructed
Polysomnography measures Apnea-hypopnea index (Minutes)
Classify and identify Obstructive Sleep Apnea Syndrome (OSAS):
Time frame: From enrollment to the end of treatment at 12 weeks
Mnimum-maximum values: 0-10 Higher scores mean worse outcome for pain scores
Time frame: From enrollment to the end of treatment at 12 weeks
pain pressure treshold measurements unit: kg/m2 Higher scores mean better outcome
Time frame: From enrollment to the end of treatment at 12 weeks
min-max scores:0-72 measures disability Higher scores mean worse outcome
Time frame: From enrollment to the end of treatment at 12 weeks"
measures disability level of patients with Fibromyalgia min-max scores: 0-100 Higher scores mean worse outcome
Time frame: From enrollment to the end of treatment at 12 weeks
measures sleep quality min-max scores: 0-24 score between 16-24 on this scale is considered increased daytime sleepiness
Time frame: From enrollment to the end of treatment at 12 weeks
measures depression level min-max values: 0-63 Higher scores mean worse outcome
Haydarpasa Numune Training and Research Hospital
Other
The Incidence of Fibromyalgia in Patients with OUAS and the Effect of CPAP Treatment on Fibromiyalgia Symptom Severity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05941780
Central Sensitisation, Chronic Pain Syndrome
Denizli, Turkey (Türkiye)
View Trial DetailsNCT05361577
Fibromyalgia, Fibromyalgia, Primary
Créteil, France
View Trial DetailsNCT04771260
Fibromyalgia, Fibromyalgia, Primary
London, United Kingdom
View Trial DetailsNCT03905486
Fibromyalgia, Fibromyalgia, Primary
Alexandria, Egypt
View Trial Details